Pneumothorax as adverse event in patients with lung metastases of soft tissue sarcoma treated with pazopanib: a single reference centre case series

BACKGROUND: Recently, the phase III PALETTE study introduced pazopanib (Votrient®) as treatment for adult patients with locally advanced or metastatic non-liposarcoma soft tissue sarcoma after prior treatment with doxorubicin and/or ifosfamide. Pneumothorax was reported as adverse event in 8 of 246...

Descripción completa

Detalles Bibliográficos
Autores principales: Verschoor, Arie J, Gelderblom, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4191680/
https://www.ncbi.nlm.nih.gov/pubmed/25302110
http://dx.doi.org/10.1186/2045-3329-4-14

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4191680/
https://www.ncbi.nlm.nih.gov/pubmed/25302110
http://dx.doi.org/10.1186/2045-3329-4-14

Ejemplares similares